Adimab, LLC - 10 Aug 2021 Form 4 Insider Report for Adagio Therapeutics, Inc. (IVVD)

Role: 10%+ Owner
Signature: /s/ Philip Chase, General Counsel
Issuer symbol: IVVD
Transactions as of: 10 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 12 Aug 2021, 21:22:40 UTC
Previous filing: 05 Aug 2021
Next filing: 01 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IVVD	Common Stock	Conversion of derivative security		+25,860,700	+1303%		27,845,995	10 Aug 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IVVD	Series A Preferred Stock	Conversion of derivative security	$0	-5,000,000	-100%	$0.000000^*	0	10 Aug 2021	Common Stock	25,000,000		Direct	F1
transaction	IVVD	Series B Preferred Stock	Conversion of derivative security	$0	-44,076	-100%	$0.000000^*	0	10 Aug 2021	Common Stock	220,380		Direct	F1
transaction	IVVD	Series C Preferred Stock	Conversion of derivative security	$0	-128,064	-100%	$0.000000^*	0	10 Aug 2021	Common Stock	640,320		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.